How Does IMBRUVICA® (ibrutinib) Work?

HomeCLL/SLLHow Does IMBRUVICA® Work?

IMBRUVICA® Is an Oral, Once-Daily CLL/SLL Medicine That Works Differently Than Chemotherapy1,2

B cells need a protein called
Bruton’s tyrosine kinase (BTK) to survive.

BTK sends signals that help B cells stay alive and multiply. In CLL/SLL, some of these B cells are cancerous.

IMBRUVICA® binds to BTK, which in turn blocks these signals. This helps stop B cells, including cancerous B cells, from surviving and slows the spread of CLL or SLL.

B cells need a protein called
Bruton’s tyrosine kinase (BTK) to survive.

BTK sends signals that help B cells stay alive and multiply. In CLL/SLL, some of these B cells are cancerous.

IMBRUVICA® binds to BTK, which in turn blocks these signals. This helps stop B cells, including cancerous B cells, from surviving and slows the spread of CLL or SLL.

Because of how IMBRUVICA® works, it may cause side effects. A relationship between how IMBRUVICA® works and why it helps to treat CLL has not been clearly identified.

You may experience changes in your white blood cell count1,3 

After starting IMBRUVICA®, your doctor will perform blood tests to measure the kind and number of cells in your blood. Your lab results may show an increase in lymphocytes, a type of white blood cell. This is called lymphocytosis and can occur with IMBRUVICA® treatment. In the absence of other signs and symptoms, this increase may not necessarily mean your condition is worsening. 
 
In 3 IMBRUVICA® clinical trials, about 2 out of 3 (66%) people with CLL/SLL taking IMBRUVICA® developed lymphocytosis. This usually happened during the first month that people started taking IMBRUVICA®. How long lymphocytosis lasted varied. It went away by a median† of 14 weeks (range of less than 1 day to 26 months). 

†Median is the middle number in a group of numbers that are arranged from lowest to highest. For example, in the group of numbers 1-11, 6 is the median.

IMBRUVICA® By Your Side Patient Support Program

Patient Support

Have questions about IMBRUVICA®? From cost and coverage options to Ambassador support—we're here to help.*

Explore Support Options
Thinking about treatment with IMBRUVICA®?

Sign up today to receive the latest information and helpful resources.

Register Now

IMBRUVICA® By Your Side patient support program is not intended to provide medical advice, replace prescribed treatment plans, or provide treatment or case management services. Patients are advised to talk to their healthcare provider and treatment team about any medical decisions and concerns they may have. By Your Side Ambassadors are provided by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie Company, and do not work under the direction of your healthcare professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

References: 1. IMBRUVICA® (ibrutinib) Prescribing Information. 2. National Institutes of Health. Isolated growth hormone deficiency. Accessed August 23, 2022. https://medlineplus.gov/genetics/condition/isolated-growth-hormone-deficiency/ 3. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. 

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at
https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).

© Pharmacyclics LLC 2023

© Janssen Biotech, Inc. 2023

09/23 PRC-10335